Fulcrum Asset Management LLP Purchases 30,039 Shares of Caris Life Sciences, Inc. $CAI

Fulcrum Asset Management LLP purchased a new position in shares of Caris Life Sciences, Inc. (NASDAQ:CAI) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 30,039 shares of the company’s stock, valued at approximately $948,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of CAI. Brighton Jones LLC acquired a new position in Caris Life Sciences in the third quarter valued at $1,161,000. Pictet Asset Management Holding SA purchased a new stake in shares of Caris Life Sciences in the third quarter valued at about $425,000. Alps Advisors Inc. purchased a new position in shares of Caris Life Sciences during the third quarter worth about $908,000. Allegiance Financial Group Advisory Services LLC purchased a new position in shares of Caris Life Sciences during the third quarter worth about $241,000. Finally, Kestra Advisory Services LLC increased its position in Caris Life Sciences by 2.5% in the 3rd quarter. Kestra Advisory Services LLC now owns 28,801 shares of the company’s stock valued at $882,000 after acquiring an additional 711 shares during the period.

Caris Life Sciences Stock Down 2.2%

CAI stock opened at $23.96 on Friday. The company has a current ratio of 6.71, a quick ratio of 5.84 and a debt-to-equity ratio of 0.61. The company’s 50-day moving average price is $29.43 and its 200 day moving average price is $21.72. Caris Life Sciences, Inc. has a 52 week low of $14.19 and a 52 week high of $36.50. The company has a market cap of $6.87 billion, a P/E ratio of 72.61, a P/E/G ratio of 7.98 and a beta of 0.71.

Caris Life Sciences (NASDAQ:CAI) last issued its earnings results on Wednesday, November 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.03 by $0.02. Caris Life Sciences had a net margin of 9.16% and a return on equity of 16.00%. The company had revenue of $275.36 million during the quarter. During the same period last year, the business posted $0.08 earnings per share. The company’s quarterly revenue was up 27.0% on a year-over-year basis. On average, research analysts expect that Caris Life Sciences, Inc. will post 0.11 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

CAI has been the subject of several analyst reports. Piper Sandler upped their price objective on Caris Life Sciences from $22.00 to $25.00 and gave the company a “neutral” rating in a research note on Tuesday. Weiss Ratings upgraded Caris Life Sciences from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday. Citigroup lifted their target price on Caris Life Sciences from $28.00 to $36.00 and gave the company a “buy” rating in a research note on Friday, November 6th. UBS Group set a $38.00 target price on Caris Life Sciences in a report on Thursday, November 5th. Finally, TD Cowen upped their price target on Caris Life Sciences from $36.00 to $38.00 and gave the stock a “buy” rating in a research note on Thursday, November 5th. Eight research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $31.18.

Insider Transactions at Caris Life Sciences

In related news, insider Brian J. Brille sold 400,000 shares of the firm’s stock in a transaction that occurred on Thursday, September 17th. The stock was sold at an average price of $30.33, for a total value of $12,132,000.00. Following the completion of the transaction, the insider directly owned 230,303 shares of the company’s stock, valued at $6,985,089.99. This trade represents a 63.46% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, President David Spetzler sold 119,212 shares of Caris Life Sciences stock in a transaction on Friday, September 4th. The stock was sold at an average price of $24.76, for a total value of $2,951,689.12. Following the transaction, the president directly owned 1,182,871 shares of the company’s stock, valued at approximately $29,287,885.96. This represents a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 1,004,712 shares of company stock valued at $27,205,419 in the last quarter. 50.00% of the stock is currently owned by corporate insiders.

About Caris Life Sciences

Caris Life Sciences is a precision medicine company that develops molecular profiling and artificial intelligence technologies to support cancer diagnosis and treatment decisions. Its services analyze the biological characteristics of a patient’s tumor to help physicians identify information that may guide care. The company’s offerings include tumor profiling based on DNA and RNA analysis, as well as blood-based testing. Caris also provides molecular data and research services to biopharmaceutical companies to support drug development and the study of cancer.